Temozolomide

Where the papers sit

31 papers from the last 6 months study temozolomide directly · updated from PubMed 10 Oct 2026

• Glioma Treatment and Resistance

  Clinical management spans low-grade and high-grade glioma, with outcomes shaped by WHO grade and MGMT promoter methylation. Temozolomide is being tested against radiotherapy, in rechallenge strategies, and in pediatric chemoradiotherapy. Resistance and toxicity remain central concerns, alongside biomarkers such as ERP44, SLC31A1 and miR-25-3p. Local and intranasal lipid-based delivery aims to improve brain targeting and combine temozolomide with other therapies.

  12 papers · 38.7%

• Temozolomide Resistance in Glioblastoma

  Glioblastoma resistance research is shifting toward druggable signaling, RNA regulation and tumor-state vulnerabilities. MET-YANK2-NEDD4L, USP5-RSK1, and METTL3-CBX5 pathways sustain resistance, while circMLB-driven stress granules offer another target. Patient-derived organoids and WYZ-1 models support personalized testing, including alternatives for resistant disease. Combination strategies pair temozolomide with nNOS inhibition, siRNA delivery or photothermal therapy, but clinical translation remains open.

  10 papers · 32.3%

• Glioblastoma Signaling and Sensitization

  Glioblastoma research is moving toward mechanism-guided sensitization rather than temozolomide alone. O-GlcNAc signaling, YAP1-Hippo control of stemness and lipid metabolism, and UFMylation are emerging therapeutic targets. Trichodermin and alantolactone combine cell-cycle or apoptosis effects with enhanced temozolomide activity. Immune and single-cell profiling increasingly connect tumor-cell pathways with macrophage and microenvironmental responses.

  7 papers · 22.6%

• Relapsed Neuroblastoma Chemoimmunotherapy

  Relapsed or refractory neuroblastoma treatment centers on combining dinutuximab-based immunotherapy with cytotoxic chemotherapy. Irinotecan, vincristine and temozolomide are being evaluated in pediatric chemoimmunotherapy schedules. The main endpoints are long-term survival and progression-free survival, with age and baseline risk shaping outcomes. The small evidence base leaves the relative contribution and durability of each component unresolved.

  2 papers · 6.5%